645 related articles for article (PubMed ID: 33580742)
21. Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.
Startin CM; Ashton NJ; Hamburg S; Hithersay R; Wiseman FK; Mok KY; Hardy J; Lleó A; Lovestone S; Parnetti L; Zetterberg H; Hye A; ; Strydom A
Alzheimers Res Ther; 2019 Mar; 11(1):26. PubMed ID: 30902060
[TBL] [Abstract][Full Text] [Related]
22. Plasma P-tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease.
Chong JR; Ashton NJ; Karikari TK; Tanaka T; Saridin FN; Reilhac A; Robins EG; Nai YH; Vrooman H; Hilal S; Zetterberg H; Blennow K; Lai MKP; Chen CP
Alzheimers Dement; 2021 Oct; 17(10):1649-1662. PubMed ID: 33792168
[TBL] [Abstract][Full Text] [Related]
23. Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study.
Zhang Y; Ferreira PCL; Jacobsen E; Bellaver B; Pascoal TA; Snitz BE; Chang CH; Villemagne VL; Ganguli M; Karikari TK
Alzheimers Dement; 2024 Jun; 20(6):4199-4211. PubMed ID: 38753951
[TBL] [Abstract][Full Text] [Related]
24. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration.
Thijssen EH; La Joie R; Wolf A; Strom A; Wang P; Iaccarino L; Bourakova V; Cobigo Y; Heuer H; Spina S; VandeVrede L; Chai X; Proctor NK; Airey DC; Shcherbinin S; Duggan Evans C; Sims JR; Zetterberg H; Blennow K; Karydas AM; Teunissen CE; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Rabinovici GD; Dage JL; Rojas JC; Boxer AL;
Nat Med; 2020 Mar; 26(3):387-397. PubMed ID: 32123386
[TBL] [Abstract][Full Text] [Related]
26. Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population.
Ohara T; Tatebe H; Hata J; Honda T; Shibata M; Matsuura S; Mikami T; Maeda T; Ono K; Mimura M; Nakashima K; Iga JI; Takebayashi M; Tokuda T; Ninomiya T;
Psychiatry Clin Neurosci; 2024 Jun; 78(6):362-371. PubMed ID: 38606661
[TBL] [Abstract][Full Text] [Related]
27. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
28. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
Simrén J; Leuzy A; Karikari TK; Hye A; Benedet AL; Lantero-Rodriguez J; Mattsson-Carlgren N; Schöll M; Mecocci P; Vellas B; Tsolaki M; Kloszewska I; Soininen H; Lovestone S; Aarsland D; ; Hansson O; Rosa-Neto P; Westman E; Blennow K; Zetterberg H; Ashton NJ
Alzheimers Dement; 2021 Jul; 17(7):1145-1156. PubMed ID: 33491853
[TBL] [Abstract][Full Text] [Related]
29. Clinical Significance of the Plasma Biomarker Panels in Amyloid-Negative and Tau PET-Positive Amnestic Patients: Comparisons with Alzheimer's Disease and Unimpaired Cognitive Controls.
Chang HI; Huang KL; Huang CG; Huang CW; Huang SH; Lin KJ; Chang CC
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891795
[TBL] [Abstract][Full Text] [Related]
30. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.
Janelidze S; Palmqvist S; Leuzy A; Stomrud E; Verberk IMW; Zetterberg H; Ashton NJ; Pesini P; Sarasa L; Allué JA; Teunissen CE; Dage JL; Blennow K; Mattsson-Carlgren N; Hansson O
Alzheimers Dement; 2022 Feb; 18(2):283-293. PubMed ID: 34151519
[TBL] [Abstract][Full Text] [Related]
31. Risk of Alzheimer's Disease is Associated with Longitudinal Changes in Plasma Biomarkers in the Multiethnic Washington Heights, Inwood Columbia Aging Project Cohort.
Gu Y; Honig LS; Kang MS; Bahl A; Sanchez D; Reyes-Dumeyer D; Manly JJ; Lantigua RA; Dage JL; Brickman AM; Vardarajan BN; Mayeux R
medRxiv; 2023 Aug; ():. PubMed ID: 37645764
[TBL] [Abstract][Full Text] [Related]
32. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
33. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
[TBL] [Abstract][Full Text] [Related]
34. Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds.
McCarter SJ; Lesnick TG; Lowe VJ; Rabinstein AA; Przybelski SA; Algeciras-Schimnich A; Ramanan VK; Jack CR; Petersen RC; Knopman DS; Boeve BF; Kantarci K; Vemuri P; Mielke MM; Graff-Radford J
J Alzheimers Dis; 2022; 87(4):1537-1547. PubMed ID: 35527558
[TBL] [Abstract][Full Text] [Related]
35. Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults.
Yu L; Boyle PA; Janelidze S; Petyuk VA; Wang T; Bennett DA; Hansson O; Schneider JA
Acta Neuropathol; 2023 Jul; 146(1):1-11. PubMed ID: 37031430
[TBL] [Abstract][Full Text] [Related]
36. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
[TBL] [Abstract][Full Text] [Related]
37. Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease.
Shi Y; Lu X; Zhang L; Shu H; Gu L; Wang Z; Gao L; Zhu J; Zhang H; Zhou D; Zhang Z
ACS Chem Neurosci; 2019 Aug; 10(8):3479-3485. PubMed ID: 31145586
[TBL] [Abstract][Full Text] [Related]
38. Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.
Palmqvist S; Tideman P; Cullen N; Zetterberg H; Blennow K; ; Dage JL; Stomrud E; Janelidze S; Mattsson-Carlgren N; Hansson O
Nat Med; 2021 Jun; 27(6):1034-1042. PubMed ID: 34031605
[TBL] [Abstract][Full Text] [Related]
39. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.
Ashton NJ; Puig-Pijoan A; Milà-Alomà M; Fernández-Lebrero A; García-Escobar G; González-Ortiz F; Kac PR; Brum WS; Benedet AL; Lantero-Rodriguez J; Day TA; Vanbrabant J; Stoops E; Vanmechelen E; Triana-Baltzer G; Moughadam S; Kolb H; Ortiz-Romero P; Karikari TK; Minguillon C; Hernández Sánchez JJ; Navalpotro-Gómez I; Grau-Rivera O; María Manero R; Puente-Periz V; de la Torre R; Roquer J; Dage JL; Zetterberg H; Blennow K; Suárez-Calvet M
Alzheimers Dement; 2023 May; 19(5):1913-1924. PubMed ID: 36370462
[TBL] [Abstract][Full Text] [Related]
40. [Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease].
Blennow K; Hansson O
Lakartidningen; 2024 May; 121():. PubMed ID: 38818759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
